Keywords: abbott, licenses, eisai, cancer, drug, adds, correction

Abbott licenses Eisai cancer drug (adds correction)

Article | 13 July 2000

Print This

Abbott Laboratories has signed a licensing agreement for Eisai'sE7010, which is currently in Phase I development for the treatment of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in